NASDAQ: ALKSAlkermes PLC Stock
$48.99-1.04 (-2.08%)
Updated Jul 31, 2026
ALKS Price
$48.99
Fair Value Price
$58.16
Market Cap
$8.22B
52 Week Low
$25.17
52 Week High
$55.67
P/E
122.48x
P/B
4.54x
P/S
5.25x
PEG
2.09x
Dividend Yield
N/A
Revenue
$1.67B
Earnings
$66.12M
Gross Margin
84.6%
Operating Margin
9.38%
Profit Margin
4%
Debt to Equity
1.43
Operating Cash Flow
$251M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALKS Overview
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALKS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
C
ALKS
Ranked#27 of 56
Ranked#27 of 56
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $40.01 | A | |
| $6.89 | A | |
| $18.32 | A |
Be the first to know about important ALKS news, forecast changes, insider trades & much more!
ALKS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALKS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALKS ($48.99) is undervalued by 15.77% relative to our estimate of its Fair Value price of $58.16 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ALKS ($48.99) is not significantly undervalued (15.77%) relative to our estimate of its Fair Value price of $58.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALKS ($48.99) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more ALKS due diligence checks available for Premium users.
Valuation
ALKS fair value
Fair Value of ALKS stock based on Discounted Cash Flow (DCF)
Price
$48.99
Fair Value
$58.16
Undervalued by
15.77%
ALKS ($48.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALKS ($48.99) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALKS ($48.99) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALKS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
122.48x
Industry
-3.99x
Market
16.13x
ALKS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ALKS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ALKS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.54x
Industry
1.59x
ALKS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALKS price to earnings growth (PEG)
For valuing profitable companies with growth potential
ALKS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ALKS's financial health
Profit margin
Revenue
$496.0M
Net Income
$501.0k
Profit Margin
0.1%
ALKS's Earnings (EBIT) of $156.41M... subscribe to Premium to read more.
Interest Coverage Financials
ALKS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.4B
Liabilities
$2.6B
Debt to equity
1.43
ALKS's short-term assets ($1.52B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALKS's long-term liabilities ($1.92B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALKS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALKS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$145.2M
Investing
-$2.4M
Financing
$17.2M
ALKS's operating cash flow ($251.18M)... subscribe to Premium to read more.
Debt Coverage Financials
ALKS vs Pharmaceutical Stocks
Alkermes Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.